Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

January 22, 2026 by InsiderTrades.com

Key Points

CEO Roger Susi sold 5,000 shares on Jan. 20 at an average price of $101.84 for $509,200, leaving him with 2,267,500 shares (a 0.22% reduction); the sale was disclosed in an SEC filing.
iRadimed beat Q results with $0.47 EPS vs. $0.43 expected and $21.2M revenue, issued Q4 2025 guidance of $0.470–0.510 and FY2025 guidance of $1.840–1.880, and paid a special $0.50 dividend on Dec. 30.
The stock trades near its 1-year high (recent open $103.22) with a market capitalization of $1.31B and a P/E of 62.56; analysts have a consensus "Moderate Buy" rating and a $95 price target.

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $101.84, for a total transaction of $509,200.00. Following the completion of the sale, the chief executive officer directly owned 2,267,500 shares of the company's stock, valued at $230,922,200. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

iRadimed Trading Up 0.2%

iRadimed stock opened at $103.22 on Thursday. iRadimed Corporation has a 1-year low of $47.48 and a 1-year high of $104.04. The firm's fifty day simple moving average is $95.43 and its 200-day simple moving average is $79.24. The company has a market capitalization of $1.31 billion, a P/E ratio of 62.56 and a beta of 1.09.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.04. The firm had revenue of $21.20 million during the quarter, compared to analysts' expectations of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, equities research analysts predict that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Announces Dividend

The company also recently declared a special dividend, which was paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th were given a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed's dividend payout ratio (DPR) is currently 41.21%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a "buy (b-)" rating on shares of iRadimed in a research note on Monday, December 29th. Zacks Research upgraded shares of iRadimed to a "hold" rating in a report on Tuesday, November 4th. Roth Mkm set a $90.00 price target on iRadimed in a research report on Friday, October 31st. Lake Street Capital reissued a "buy" rating and set a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Finally, Wall Street Zen downgraded iRadimed from a "strong-buy" rating to a "buy" rating in a research note on Sunday, October 26th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $95.00.

Get Our Latest Report on IRMD

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IRMD. CWM LLC lifted its stake in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 211 shares during the period. Quarry LP acquired a new position in iRadimed in the 3rd quarter valued at approximately $40,000. State of Alaska Department of Revenue bought a new stake in shares of iRadimed in the 3rd quarter worth approximately $47,000. Tower Research Capital LLC TRC grew its holdings in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 495 shares in the last quarter. Finally, USA Financial Formulas bought a new stake in shares of iRadimed during the fourth quarter valued at approximately $82,000. Institutional investors and hedge funds own 92.34% of the company's stock.

iRadimed Company Profile

(Get Free Report)

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.